Gestational Diabetes and the Metabolic Syndrome: Can Obesity and Small, Dense Low Density Lipoproteins be Key Mediators of this Association?

ISSN: 1873-4316 (Online)
ISSN: 1389-2010 (Print)


Volume 17, 15 Issues, 2016


Download PDF Flyer




Current Pharmaceutical Biotechnology

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 152nd of 255 in Pharmacology & Pharmacy
  • 213th of 290 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Zeno Foldes-Papp
Christian Clinical Center Siegen-Kreuztal
Siegen-Kreuztal
Germany


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 1.95
5 - Year: 2.558

Gestational Diabetes and the Metabolic Syndrome: Can Obesity and Small, Dense Low Density Lipoproteins be Key Mediators of this Association?



Current Pharmaceutical Biotechnology, 15(1): 38-46.

Author(s): Ali A. Rizvi, Silvia Cuadra, Dragana Nikolic, Rosaria V. Giglio, Giuseppe Montalto and Manfredi Rizzo.

Affiliation: Biomedical Department of Internal Medicine and Medical Specialties, University of Palermo, Via del Vespro, 141, 90127, Palermo, Italy.

Abstract

Gestational diabetes mellitus (GDM) represents a condition of glucose intolerance with first appearance or recognition at the time of a pregnancy, associated with an inadequate pancreatic response to the advanced insulin resistance of the later stages of pregnancy, and accompanied by enhancing β-cell mass and secretion of insulin. Women who had GDM exhibit a higher risk for later advent of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD). Additionally, previous GDM has been proposed as independently correlated with higher risk for development of atherosclerosis in a healthy population, similar to the metabolic syndrome (MetS) and independently of the presence of established CVD risk factors. Available data indicate multiple metabolic abnormalities common in women with GDM, including a high small dense low-density lipoprotein (sdLDL) concentration and a resultant high prevalence of CVD and the MetS. Preliminary data indicate that a measurement of sdLDL is worthwhile in women with GDM during pregnancy as well as the postpartum period. A close follow up of these women should be emphasized in clinical practice because GDM could predict not only eventual health risks for these mothers, but also their offspring. Thus, an improvement in care and risk modification of women with GDM may not only contribute towards improved CVD profile, but also potentially prevent adverse outcomes in their offspring. Lifestyle changes should be promoted in order to prevent excessive weight gain during pregnancy and decrease the risk of MetS in the postpartum and long-term.

Keywords:

Cardiovascular diseases, cardiovascular risk, gestational diabetes mellitus, metabolic syndrome, small dense lowdensity lipoprotein, type 2 diabetes mellitus.



Download Free Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 15
Issue Number: 1
First Page: 38
Last Page: 46
Page Count: 9
DOI: 10.2174/1389201015666140330193653
Advertisement
BIOtech JapanBIOtech JapanBIOtech JapanGlobal Biotechnology Congress 2016Drug Discovery and Therapy World Congress 2016

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science